Shridar Ganesan

Dr. Shridar Ganesan


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2010 in Nature Structural & Molecular Biology
Verified
Journal Article
Open access
PDF file
PBPeter Bouwman
Peter Bouwman
AAAmal Aly
Amal Aly
JEJose Miguel Escandell
Jose Miguel Escandell
MPMark Pieterse
Mark Pieterse
JBJirina Bartkova
Jirina Bartkova
JJJos Jonkers
Jos Jonkers
A transposon mutagenesis screen indicates that loss of 53BP1 expression rescues the clonal growth defect of BRCA1 null cells. 53BP1 deficiency is shown to abrogate the cell cycle arrest triggered in the absence of BRCA1 and to partially restore homologous recombination. The potential clinical implications of these findings are supported by the reduction of 53BP1 expression in sporadic triple-negative and BRCA-associated breast cancers. Germ-line mutations in breast cancer 1, early onset (BRCA1) result in predisposition to breast and ovarian cancer. BRCA1-mutated tumors show genomic instability, mainly as a consequence of impaired recombinatorial DNA repair. Here we identify p53-binding protein 1 (53BP1) as an essential factor for sustaining the growth arrest induced by Brca1 deletion. Depletion of 53BP1 abrogates the ATM-dependent checkpoint response and G2 cell-cycle arrest triggered by the accumulation of DNA breaks in Brca1-deleted cells. This effect of 53BP1 is specific to BRCA1 function, as 53BP1 depletion did not alleviate proliferation arrest or checkpoint responses in Brca2-deleted cells. Notably, loss of 53BP1 partially restores the homologous-recombination defect of Brca1-deleted cells and reverts their hypersensitivity to DNA-damaging agents. We find reduced 53BP1 expression in subsets of sporadic triple-negative and BRCA-associated breast cancers, indicating the potential clinical implications of our findings.

1 February 2006 in Cancer Cell
Verified
Journal Article
Closed access
ARAndrea L. Richardson
Andrea L. Richardson
ZWZhigang C. Wang
Zhigang C. Wang
ANArcangela De Nicolo
Arcangela De Nicolo
XLXin Lu
Xin Lu
MBMyles Brown
Myles Brown
SGShridar Ganesan
Shridar Ganesan

10 April 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
DCDebyani Chakravarty
Debyani Chakravarty
AJAmber Johnson
Amber Johnson
JSJeffrey Sklar
Jeffrey Sklar
NLNeal I. Lindeman
Neal I. Lindeman
KMKathleen Moore
Kathleen Moore
FMFunda Meric-Bernstam
Funda Meric-Bernstam
PURPOSE: An ASCO provisional clinical opinion offers timely clinical direction to ASCO's membership following publication or presentation of potentially practice-changing data from major studies. This provisional clinical opinion addresses the appropriate use of tumor genomic testing in patients with metastatic or advanced solid tumors.CLINICAL CONTEXT: An increasing number of therapies are approved to treat cancers harboring specific genomic biomarkers. However, there is a lack of clarity as to when tumor genomic sequencing should be ordered, what type of assays should be performed, and how to interpret the results for treatment selection.PROVISIONAL CLINICAL OPINION: Patients with metastatic or advanced cancer should undergo genomic sequencing in a certified laboratory if the presence of one or more specific genomic alterations has regulatory approval as biomarkers to guide the use of or exclusion from certain treatments for their disease. Multigene panel–based assays should be used if more than one biomarker-linked therapy is approved for the patient's disease. Site-agnostic approvals for any cancer with a high tumor mutation burden, mismatch repair deficiency, or neurotrophic tyrosine receptor kinase ( NTRK) fusions provide a rationale for genomic testing for all solid tumors. Multigene testing may also assist in treatment selection by identifying additional targets when there are few or no genotype-based therapy approvals for the patient's disease. For treatment planning, the clinician should consider the functional impact of the targeted alteration and expected efficacy of genomic biomarker–linked options relative to other approved or investigational treatments. Additional information is available at www.asco.org/assays-and-predictive-markers-guidelines .

1 May 2011 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
VGVasudeva Ginjala
Vasudeva Ginjala
KNKarim Nacerddine
Karim Nacerddine
AKAtul Kulkarni
Atul Kulkarni
JOJay Oza
Jay Oza
SHSarah J. Hill
Sarah J. Hill
SGShridar Ganesan
Shridar Ganesan
DNA damage activates signaling pathways that lead to modification of local chromatin and recruitment of DNA repair proteins. Multiple DNA repair proteins having ubiquitin ligase activity are recruited to sites of DNA damage, where they ubiquitinate histones and other substrates. This DNA damage-induced histone ubiquitination is thought to play a critical role in mediating the DNA damage response. We now report that the polycomb protein BMI1 is rapidly recruited to sites of DNA damage, where it persists for more than 8 h. The sustained localization of BMI1 to damage sites is dependent on intact ATM and ATR and requires H2AX phosphorylation and recruitment of RNF8. BMI1 is required for DNA damage-induced ubiquitination of histone H2A at lysine 119. Loss of BMI1 leads to impaired repair of DNA double-strand breaks by homologous recombination and the accumulation of cells in G2/M. These data support a crucial role for BMI1 in the cellular response to DNA damage.

27 April 2010 in BMC Systems Biology
Verified
Journal Article
Open access
PDF file
HLHuiqing Liu
Huiqing Liu
ABAngela R Brannon
Angela R Brannon
ARAnupama R Reddy
Anupama R Reddy
GAGabriela Alexe
Gabriela Alexe
MSMichael W Seiler
Michael W Seiler
GBGyan Bhanot
Gyan Bhanot
Background: MicroRNA regulate mRNA levels in a tissue specific way, either by inducing degradation of the transcript or by inhibiting translation or transcription. Putative mRNA targets of microRNA identified from seed sequence matches are available in many databases. However, such matches have a high false positive rate and cannot identify tissue specificity of regulation.Results: We describe a simple method to identify direct mRNA targets of microRNA dysregulated in cancers from expression level measurements in patient matched tumor/normal samples. The word "direct" is used here in a strict sense to: a) represent mRNA which have an exact seed sequence match to the microRNA in their 3'UTR, b) the seed sequence match is strictly conserved across mouse, human, rat and dog genomes, c) the mRNA and microRNA expression levels can distinguish tumor from normal with high significance and d) the microRNA/mRNA expression levels are strongly and significantly anti-correlated in tumor and/or normal samples. We apply and validate the method using clear cell Renal Cell Carcinoma (ccRCC) and matched normal kidney samples, limiting our analysis to mRNA targets which undergo degradation of the mRNA transcript because of a perfect seed sequence match. Dysregulated microRNA and mRNA are first identified by comparing their expression levels in tumor vs normal samples. Putative dysregulated microRNA/mRNA pairs are identified from these using seed sequence matches, requiring that the seed sequence be conserved in human/dog/rat/mouse genomes. These are further pruned by requiring a strong anti-correlation signature in tumor and/or normal samples. The method revealed many new regulations in ccRCC. For instance, loss of miR-149, miR-200c and mir-141 causes gain of function of oncogenes (KCNMA1, LOX), VEGFA and SEMA6A respectively and increased levels of miR-142-3p, miR-185, mir-34a, miR-224, miR-21 cause loss of function of tumor suppressors LRRC2, PTPN13, SFRP1, ERBB4, and (SLC12A1, TCF21) respectively. We also found strong anti-correlation between VEGFA and the miR-200 family of microRNA: miR-200a*, 200b, 200c and miR-141. Several identified microRNA/mRNA pairs were validated on an independent set of matched ccRCC/normal samples. The regulation of SEMA6A by miR-141 was verified by a transfection assay.Conclusions: We describe a simple and reliable method to identify direct gene targets of microRNA in any cancer. The constraints we impose (strong dysregulation signature for microRNA and mRNA levels between tumor/normal samples, evolutionary conservation of seed sequence and strong anti-correlation of expression levels) remove spurious matches and identify a subset of robust, tissue specific, functional mRNA targets of dysregulated microRNA.

1 August 2013 in IEEE Transactions on Biomedical Engineering
Verified
Journal Article
Closed access
ABAjay Basavanhally
Ajay Basavanhally
SGShridar Ganesan
Shridar Ganesan
MFMichael Feldman
Michael Feldman
NSNatalie Shih
Natalie Shih
CMCarolyn Mies
Carolyn Mies
Anant MadabhushiAnant Madabhushi
Anant Madabhushi
Modified Bloom-Richardson (mBR) grading is known to have prognostic value in breast cancer (BCa), yet its use in clinical practice has been limited by intra- and interobserver variability. The development of a computerized system to distinguish mBR grade from entire estrogen receptor-positive (ER+) BCa histopathology slides will help clinicians identify grading discrepancies and improve overall confidence in the diagnostic result. In this paper, we isolate salient image features characterizing tumor morphology and texture to differentiate entire hematoxylin and eosin (H and E) stained histopathology slides based on mBR grade. The features are used in conjunction with a novel multifield-of-view (multi-FOV) classifier-a whole-slide classifier that extracts features from a multitude of FOVs of varying sizes-to identify important image features at different FOV sizes. Image features utilized include those related to the spatial arrangement of cancer nuclei (i.e., nuclear architecture) and the textural patterns within nuclei (i.e., nuclear texture). Using slides from 126 ER+ patients (46 low, 60 intermediate, and 20 high mBR grade), our grading system was able to distinguish low versus high, low versus intermediate, and intermediate versus high grade patients with area under curve values of 0.93, 0.72, and 0.74, respectively. Our results suggest that the multi-FOV classifier is able to 1) successfully discriminate low, medium, and high mBR grade and 2) identify specific image features at different FOV sizes that are important for distinguishing mBR grade in Hand E stained ER+ BCa histology slides.